On March 31, INNOVENT BIO announced that its globally pioneering PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 has been included in the list of breakthrough therapeutic drugs (BTD) by the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) of China, with the intended indication being unresectable locally advanced or metastatic acral and mucosal melanoma that has not previously undergone systemic treatment.
Clear
All
Quotes
News
Learn
Help
All
HK
US
CN
SG
AU
JP
CA
MY
All
News
Announcements
Reports
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh
Refresh
Loading
History record
Latest News
-
U.S. Treasury Secretary Bennett: The Trump administration promotes reforms in trade and tax policies, aiming for a win-win situation of manufacturing return and fiscal revenue.
HSBC Holdings Q1 performance exceeded expectations! Announced a buyback of up to 3 billion USD in Stocks.
U.S. Stock Outlook | Is Tesla's stock price seeing a turnaround? Board of Directors members have increased their shareholding in Stocks for the first time in five years; in collaboration with Novo-Nordisk A/S, Hims surged over 46% in pre-market trading; m
Quotes
More
News
More
Learn
More
Help
More
Loading
News
More
Announcements
More
Reports
More
信达生物:IBI363获国家药监局纳入突破性治疗药物品种,治疗晚期黑色素瘤
INNOVENT BIO: IBI363 has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration for the treatment of advanced melanoma.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Like
Views 805
Write a comment
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Comment(0)
Reason For Report